80881-74-9

Basic information

• Product Name: Acetamide, N-[4-hydroxy-3-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]-
• CAS NO: 80881-74-9
• Molecular Formula: C18H17NO4
• Molecular Weight: 311.337
• Mol File: 80881-74-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-hydroxy-3-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-hydroxy-3-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]-(80881-74-9)
• EPA Substance Registry System: Acetamide, N-[4-hydroxy-3-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]phenyl]-(80881-74-9)

Safety Data

• Hazardous Substances Data: 80881-74-9(Hazardous Substances Data)

Upstream product

• 103-90-2 4-acetaminophenol 
• 7298-67-1 5-acetamido-2-hydroxyacetophenone 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 80881-76-1 N-(2-(4-methoxyphenyl)-4-oxo-4H-chromen-6-yl)acetamide 
• 1245282-78-3 6-amino-3-hydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one 
• 1245282-87-4 N-(3-methoxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-6-yl)acetamide 
• 1252652-97-3 C₁₇H₁₅NO₄*ClH 
• 80881-78-3 6-amino-2-(4-methoxyphenyl)-4H-chromen-4-one 
• 102028-75-1 N-(3-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-chromen-6-yl)acetamide 
• 95561-28-7 4-acetylamino-2-[5-(4-methoxy-phenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-phenol 

Relevant articles and documents

Evaluation of in vitro and in vivo anticancer potential of two 5-acetamido chalcones against breast cancer

Two 5’acetamido chalcones, C1 and C2 were synthesized by Claisen-Schmidt condensation method and characterized by IR, LC-MS, 1H NMR and 13C NMR. These compounds were evaluated for anticancer activity in vitro in breast cancer cell lines (MCF-7 and MDA-MB-231) using MTT assay, anti-metastatic assay, apoptotic screening by AO/EB staining and in vivo in N-Methyl-N-nitrosourea (MNU) induced breast carcinoma model. Sprague-Dawley rats with developed tumors (50 mg/kg MNU i.p.) were grouped in four, namely MNU control (0.25 % of CMC p.o.), standard group (doxorubicin 2 mg/kg once in 4 days, i.p.), C1 and C2 groups (50 mg/kg p.o. each). After 21 days of treatments, tumor volume and weight were assessed. Excised tumors were subjected to DNA fragmentation study. MTT assay showed IC50 values of 62.56 and 37.8 μM by for C1 and C2. Both compounds increased apoptotic bodies more than 3 fold compared to normal control in AO/EB staining. Antimetastatic (scratch wound) assay showed a significant (p0.05) reduction in cell migration after 24 h and 48 h treatments compared to normal control. In in vivo studies, tumor weight and tumor volume were significantly (p0.05) reduced in the doxorubicin group as well as in test groups compared to MNU control. DNA fragmentation assay showed an increase in the number of bands formed in C1 and C2 compared to normal control. Results obtained from in vitro and in vivo studies demonstrated the significant anticancer potentials of C1 and C2.

COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES

This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Synthesis and complete assignment of the 1H and 13C NMR signals of new acetamido and aminoflavonoid derivatives

The complete 1H and13C NMR assignment of 9 acetamidochalcones, 18 acetamidoflavones, 18 aminoflavones, 9 acetamidoflavonols and 9 aminoflavonols has been performed using one- and two-dimensional NMR techniques including COSY, HMQC and HMBC experiments. Copyright